The aim of this study is to evaluate the efficacy and safety of short course radiotherapy followed by fruquintinib combined with Sintilimab as the first-line treatment of advanced mCRC compared to bevacizumab combined with capecitabine in patients unfit for intensive therapy.
Have signed an informed consent;
18 to 85 years old (including 18 and 85 years old);
Histopathologically confirmed unresectable advanced metastatic colorectal adenocarcinoma;
Have not received anti-tumor treatment for metastatic disease;
Currently has a disease or condition that affects drug absorption, or the patient is unable to take oral drugs;
Currently has digestive tract diseases such as active gastric and duodenal ulcers, ulcerative colitis, or active bleeding from unresectable tumors, or other conditions determined by the researcher that may cause gastrointestinal bleeding or perforation;
History of serious cardiovascular and cerebrovascular diseases;
Other malignant tumors within the past 5 years, excluding skin basal cell or squamous cell carcinoma after radical surgery, or cervical carcinoma in situ;